Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

743.52 -4.49 (-0.60%)
Streaming Delayed Price Updated: 11:23 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Should You Buy Eli Lilly Stock After Another Major Win?
It was a buy even before this development. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. 
Via Benzinga
Eli Lilly Announces CFO Change
Shares of Eli Lilly And Company (NYSE: LLY) are moving higher on Wednesday. Here's what you need to know. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
JUPITER, Fla. - July 11, 2024 - PRLog -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum... 
Via PRLog
Exposures Product Safety
3 Future Blue-Chip Stocks That Could Make You Rich
Blue-chip stocks are the cream of the crop of the stock exchange market. Find out about the best future blue-chip stocks to invest in. 
Via InvestorPlace
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
Both equities have been incredible growth plays of late. 
Via The Motley Fool
Topics ETFs
Warren Buffett Recommends This Magnificent Index Fund. It Could Turn $500 Per Month Into $986,900
The S&P 500 is a group of businesses that are bound to perform well over time, according to Warren Buffett. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's Tesla, and Eli Lilly. 
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Investors might want to consider the top pharma stocks in the current environment as they are beating most others. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on the medication after two years, raising concerns about long-term adherence. 
Via Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... 
Via Benzinga
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion – InsideArbitrage
Via AB Newswire
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
Give some consideration to these names, each of which has a strong competitive advantage and catalysts driving their share price higher. 
Via InvestorPlace
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
Want to turn your $10K into $1 million? Here are three high-growth potential stocks that can make it happen for you. 
Via InvestorPlace
Summer 2024 Snapshot Of The S&P 500's Market Cap
The market capitalization of the S&P 500 grew by 4.2% during the course of the second quarter of 2024. The index ended 2024-Q2 with a market cap of $47.83 trillion according to Standard and Poor. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases. 
Via InvestorPlace
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
No matter how you look at it, the FDA approval of Kisunla is big for Eli Lilly. 
Via The Motley Fool
Exposures Product Safety
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
This pharma company is posting double-digit revenue growth. 
Via The Motley Fool
S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone
The CNN Money Fear and Greed index slightly decreased, remaining in Neutral zone. US stocks mixed, with S&P 500 at record high. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic. 
Via Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Patients lost more more weight on Mounjaro than Ozempic. 
Via Investor's Business Daily
A $2.5 Trillion Opportunity In The Biotech Industry
In 1979, Genentech managed to create synthetic human insulin. Now 45 years later, biotech is a $1.77 trillion industry — up from $1.55 trillion in 2023. By 2030, that’s projected to reach close to $4... 
Via Talk Markets
Facebook Parent Meta Platforms Among 4 Hot Stocks At All-Time Highs: Look For The Best Stocks On These IBD Lists
Meta Platforms came aboard the Big Cap Leaders list, as did medical standout Eli Lilly. They were among four stock at all-time highs Monday. 
Via Investor's Business Daily
Gold Falls Over 1%; HilleVax Shares Plunge
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.